- Home
- FGF vs OVID Comparison
FGF vs OVID Comparison
Compare FGF & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- OVID
- Stock Information
- Founded
- FGF 2012
- OVID 2014
- Country
- FGF United States
- OVID United States
- Employees
- FGF N/A
- OVID N/A
- Industry
- FGF Property-Casualty Insurers
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- OVID Health Care
- Exchange
- FGF Nasdaq
- OVID Nasdaq
- Market Cap
- FGF 20.9M
- OVID 20.6M
- IPO Year
- FGF N/A
- OVID 2017
- Fundamental
- Price
- FGF $17.10
- OVID $0.33
- Analyst Decision
- FGF
- OVID Strong Buy
- Analyst Count
- FGF 0
- OVID 4
- Target Price
- FGF N/A
- OVID $3.13
- AVG Volume (30 Days)
- FGF 1.9K
- OVID 1.6M
- Earning Date
- FGF 08-13-2025
- OVID 08-12-2025
- Dividend Yield
- FGF N/A
- OVID N/A
- EPS Growth
- FGF N/A
- OVID N/A
- EPS
- FGF N/A
- OVID N/A
- Revenue
- FGF $13,260,000.00
- OVID $548,000.00
- Revenue This Year
- FGF N/A
- OVID N/A
- Revenue Next Year
- FGF N/A
- OVID $5.32
- P/E Ratio
- FGF N/A
- OVID N/A
- Revenue Growth
- FGF N/A
- OVID 15.61
- 52 Week Low
- FGF $14.21
- OVID $0.24
- 52 Week High
- FGF $38.40
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- FGF 50.54
- OVID 61.02
- Support Level
- FGF $16.50
- OVID $0.29
- Resistance Level
- FGF $18.87
- OVID $0.32
- Average True Range (ATR)
- FGF 0.56
- OVID 0.03
- MACD
- FGF 0.05
- OVID 0.00
- Stochastic Oscillator
- FGF 24.00
- OVID 91.03
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.